uniQure (NASDAQ:QURE) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in uniQure (NASDAQ:QURE) by 6.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 277,275 shares of the biotechnology company’s stock after buying an additional 16,464 shares during the period. Charles Schwab Investment Management Inc.’s holdings in uniQure were worth $1,367,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its stake in uniQure by 49.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after buying an additional 89,400 shares in the last quarter. Privium Fund Management B.V. increased its position in shares of uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after purchasing an additional 104,500 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of uniQure in the 2nd quarter worth approximately $79,000. abrdn plc lifted its stake in uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after acquiring an additional 1,528,581 shares in the last quarter. Finally, Atria Investments Inc purchased a new stake in uniQure during the 3rd quarter worth approximately $53,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Royal Bank of Canada increased their price target on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. StockNews.com raised uniQure to a “sell” rating in a report on Wednesday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.13.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.74% of the stock is currently owned by insiders.

uniQure Stock Performance

NASDAQ:QURE opened at $17.40 on Tuesday. The firm has a market cap of $848.13 million, a PE ratio of -3.36 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1-year low of $3.73 and a 1-year high of $17.71. The firm has a 50 day simple moving average of $7.04 and a 200-day simple moving average of $6.38.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. On average, equities analysts expect that uniQure will post -3.82 EPS for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.